S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
S&P 500   5,199.06
DOW   38,459.08
QQQ   445.37
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024
Stock market today: Global markets mixed after Wall St rebound led by Big Tech
Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
How major US stock indexes fared Thursday, 4/11/2024
Closing prices for crude oil, gold and other commodities
Carmax Returns to the Bargain Basement: Buy the Dip? 
Homebuyers’ quandary: to wait or not to wait for lower mortgage rates
NASDAQ:ANNX

Annexon (ANNX) Stock Price, News & Analysis

$6.07
-0.10 (-1.62%)
(As of 04/11/2024 ET)
Today's Range
$6.00
$6.56
50-Day Range
$4.03
$7.81
52-Week Range
$1.57
$8.40
Volume
808,777 shs
Average Volume
2.46 million shs
Market Capitalization
$546.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.43

Annexon MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
137.7% Upside
$14.43 Price Target
Short Interest
Healthy
3.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Annexon in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$49,514 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.36) to ($1.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

796th out of 2,796 stocks

Pharmaceutical Preparations Industry

322nd out of 1,203 stocks

ANNX stock logo

About Annexon Stock (NASDAQ:ANNX)

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX Stock Price History

ANNX Stock News Headlines

SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
SHOCKING Altcoin Moves…
Bitcoin's recent price boom has sent select altcoins into an absolute FRENZY! Which is why we've gathered 27 crypto experts to share their top picks and predictions as we rapidly approach the Bitcoin halving event this month…
Annexon Biosciences (ANNX) Receives a Buy from TD Cowen
ANNX Jul 2024 7.500 put
ANNX Apr 2024 2.500 call
ANNX Apr 2024 7.500 put
HRTX, LUNA and ARQ among mid-day movers
ANNX Mar 2024 10.000 put
JP Morgan Upgrades Annexon (ANNX)
Annexon Stock (NASDAQ:ANNX), Short Interest Report
See More Headlines
Receive ANNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
4/12/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANNX
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.43
High Stock Price Target
$30.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+137.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-134,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.20 per share

Miscellaneous

Free Float
72,822,000
Market Cap
$546.46 million
Optionable
Optionable
Beta
1.14
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives


ANNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Annexon stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares.
View ANNX analyst ratings
or view top-rated stocks.

What is Annexon's stock price target for 2024?

6 Wall Street research analysts have issued 12 month price targets for Annexon's shares. Their ANNX share price targets range from $7.00 to $30.00. On average, they predict the company's share price to reach $14.43 in the next year. This suggests a possible upside of 137.7% from the stock's current price.
View analysts price targets for ANNX
or view top-rated stocks among Wall Street analysts.

How have ANNX shares performed in 2024?

Annexon's stock was trading at $4.54 at the beginning of the year. Since then, ANNX stock has increased by 33.7% and is now trading at $6.07.
View the best growth stocks for 2024 here
.

Are investors shorting Annexon?

Annexon saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,590,000 shares, an increase of 44.2% from the March 15th total of 2,490,000 shares. Based on an average daily volume of 1,570,000 shares, the days-to-cover ratio is presently 2.3 days.
View Annexon's Short Interest
.

When is Annexon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ANNX earnings forecast
.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) posted its earnings results on Monday, November, 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07.

What ETFs hold Annexon's stock?

ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).iShares Neuroscience and Healthcare ETF (IBRN).

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE).

When did Annexon IPO?

Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO.

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANNX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners